Chen Jian-Jun, Zhou Chan-Juan, Zheng Peng, Cheng Ke, Wang Hai-Yang, Li Juan, Zeng Li, Xie Peng
Institute of Life Sciences, Chongqing Medical University, China; Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, China; Joint International Research Laboratory of Reproduction & Development, Chongqing Medical University, China; Institute of Neuroscience, Chongqing Medical University, China; Chongqing Key Laboratory of Neurobiology, Chongqing Medical University, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, China.
Institute of Neuroscience, Chongqing Medical University, China; Chongqing Key Laboratory of Neurobiology, Chongqing Medical University, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, China; Department of Neurology, Yongchuan Hospital of Chongqing Medical University, China.
Behav Brain Res. 2017 Aug 14;332:280-287. doi: 10.1016/j.bbr.2017.06.012. Epub 2017 Jun 15.
Major depressive disorder (MDD) is a common mental disorder that affects a person's general health. However, there is still no objective laboratory test for diagnosing MDD. Here, an integrated analysis of data from our previous studies was performed to identify the differential metabolites in the urine of moderate and severe MDD patients. A dual platform approach (NMR spectroscopy and GC-MS) was used. Consequently, 14 and 22 differential metabolites responsible for separating moderate and severe MDD patients, respectively, from their respective healthy controls (HCs) were identified. Meanwhile, the moderate MDD-specific panel (N-Methylnicotinamide, Acetone, Choline, Citrate, vanillic acid and azelaic acid) and severe MDD-specific panel (indoxyl sulphate, Taurine, Citrate, 3-hydroxyphenylacetic acid, palmitic acid and Lactate) could discriminate moderate and severe MDD patients, respectively, from their respective HCs with high accuracy. Moreover, the differential metabolites in severe MDD were significantly involved in three metabolic pathways and some biofunctions. These results showed that there were divergent urinary metabolic phenotypes in moderate and severe MDD patients, and the identified potential urinary biomarkers might be useful for future developing objective diagnostic tests for MDD diagnosis. Our results could also be helpful for researchers to study the pathogenesis of MDD.
重度抑郁症（MDD）是一种影响人的整体健康的常见精神障碍。然而，目前仍没有用于诊断MDD的客观实验室检测方法。在此，我们对之前研究的数据进行了综合分析，以确定中度和重度MDD患者尿液中的差异代谢物。采用了双平台方法（核磁共振光谱法和气相色谱 - 质谱联用）。结果，分别鉴定出14种和22种负责将中度和重度MDD患者与其各自的健康对照（HC）区分开来的差异代谢物。同时，中度MDD特异性代谢物组（N - 甲基烟酰胺、丙酮、胆碱、柠檬酸盐、香草酸和壬二酸）和重度MDD特异性代谢物组（硫酸吲哚酚、牛磺酸、柠檬酸盐、3 - 羟基苯乙酸、棕榈酸和乳酸）能够分别以高精度将中度和重度MDD患者与其各自的HC区分开来。此外，重度MDD中的差异代谢物显著参与了三种代谢途径和一些生物功能。这些结果表明，中度和重度MDD患者存在不同的尿液代谢表型，所鉴定出的潜在尿液生物标志物可能有助于未来开发用于MDD诊断的客观诊断测试。我们的结果也可能有助于研究人员研究MDD的发病机制。
